Clinical Trials Logo

Clinical Trial Summary

This study will evaluate the efficacy of anacetrapib (100 mg) for 24 weeks relative to placebo, on plasma concentrations of Low Density Lipoprotein Cholesterol and assess the safety and tolerability of anacetrapib (100 mg) in participants with CHD/CHD risk-equivalent disease on stable dose regimen of statin with or without other lipid-modifying therapy. The two year extension to this study will further evaluate the long-term safety profile and efficacy of anacetrapib in CHD/CHD-risk equivalent patients who are on ongoing therapy with a statin with or without other lipid-modifying therapy.


Clinical Trial Description

The 76 week treatment period is followed by a 12 week reversibility phase which can be extended by up to another 12 weeks in order to allow participants who have completed their week 88 visit to continue in the study until the Extension study is ready to be implemented.

In the optional extension, participants will be assigned to the same treatment arm to which they were assigned in the base study. The total duration of the extension study will be up to 116 weeks; which will include a 2 year treatment period, followed by a 12 week reversal phase. A post-extension study follow-up phone call will be completed 12 weeks after discontinuation or completion of study treatment. Participants previously treated with anacetrapib or placebo will be invited in a 4:1 ratio in an optional extended reversal phase. The total duration of the extended reversal phase will be 1 year.

Participants previously treated with anacetrapib in the DEFINE study will be followed periodically for up to 4 years to determine plasma levels of anacetrapib. Participants will also be invited to participate in a sub-study consisting of one clinic visit to measure anacetrapib levels in the plasma and the subcutaneous adipose tissue.

ACRONYM: DEFINE= Determining the EFficacy and Tolerability of Cholesteryl ester transfer protein (CETP) INhibition with AnacEtrapib ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00685776
Study type Interventional
Source Merck Sharp & Dohme Corp.
Contact
Status Completed
Phase Phase 3
Start date March 24, 2008
Completion date November 23, 2017

See also
  Status Clinical Trial Phase
Withdrawn NCT01631409 - Estimation of the Long Term Effectiveness of Routine Use of Cardiac Shock Wave Therapy N/A
Completed NCT04610892 - Efficacy and Safety of MEDI6570 in Patients With a History of Myocardial Infarction Phase 2
Recruiting NCT05834673 - VICTORION-ASCERTAIN: Implementation Study (v-ASCERTAIN) Phase 4
Active, not recruiting NCT03872401 - Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke Phase 3
Completed NCT03427489 - A Biorepository for Coronary Heart Disease in Qatar
Active, not recruiting NCT01864031 - The Role of Alcohol Consumption in the Aetiology of Different Cardiovascular Disease Phenotypes: a CALIBER Study N/A
Not yet recruiting NCT05178602 - The Effect of TaiChi on Ischemic Burden of Patients With Coronary Heart Disease Complicated With Renal Insufficiency N/A
Not yet recruiting NCT06216847 - Clinical Outcomes of Patients With Coronary Artery Disease
Recruiting NCT06170541 - CORE-COMPARE Pilot Study N/A
Recruiting NCT01315834 - Couples Coping With Coronary Heart Disease N/A